About us
Company philosophy
Virtual Science AI Ltd is on a mission to reimagine how the life sciences industry generates external stakeholder insights. These insights are delivered via our unique and ground breaking Artificial Intelligence platform. Our platform offers a wide range of features, including synchronous & asynchronous interaction, co collaboration tools and AI report generation capability.
Virtual Science AI Ltd is the first company in the industry to aggregate all interactive data from HCP and Patient panel activities which enables the connecting of data points across enterprises. This helps identify gaps, themes and answers much faster and helps inform decisions to drive organisational success.
We aim to deliver effortless services to partnering teams that free up a client’s time to move quicker and to act on meaningful insights that help bring their solutions to patients in need.
Meet our senior leaders
Tom Hughes is at the helm of Virtual Science AI Ltd, steering the company towards realizing its strategic vision of becoming the foremost global provider of virtual engagement and insight management services in the field of life sciences.
The overarching goal is to create and deploy cutting-edge advisory panel and insight management capabilities that can be seamlessly implemented across a wide spectrum of life science companies. This initiative aims to empower life science teams, enabling them to expedite the delivery of crucial treatments to patients in need.
Prior to joining Virtual Science AI Ltd, Tom served as the Global Franchise Lead at Pharmaspectra. During his tenure, he assumed pivotal roles in commercial leadership and played a key role in achieving the company’s growth objectives from 2019 to 2021. Tom’s expertise lies in the development of software as a service organizations, with a focus on establishing global organizational infrastructure and adeptly managing Profit and Loss (P&L) responsibilities.
Commencing his career as a Medical Representative in the UK, Tom embarked on a progressive journey that included seven years with Pfizer. During this time, he took on roles of increasing responsibility in sales and marketing, overseeing sales teams and brand marketing across various therapeutic areas. Notably, he undertook a global assignment at Pfizer, spearheading digital transformation initiatives for virtual selling worldwide.
Tom holds a Master of Business Administration from the University of Liverpool, United Kingdom.
Chih Han (Hans) Chen, is a Technology and AI leader. Empowering Life Science teams to win. He is a certified Data Scientist, Project Leader, PhD who built multiple successful AI/ML products. Hans is now leading the technology team at Virtual Science to apply state-of-art tech and bring life sciences advisory to the next level.
Chief Technology Officer
Geraldine Reilly joined Virtual Science AI Ltd in March 2022 as the Vice President of Patient Affairs. In January 2023, she assumed the role of Chief Operating Officer, and by May 2023, due to the expanding customer base of Virtual Science AI, she transitioned to the position of Chief Customer Officer. In this capacity, Geraldine is tasked with overseeing and ensuring the health of customer relationships.
Before her tenure at Virtual Science, Geraldine dedicated 20 years to Gilead Sciences, progressing through roles of increasing responsibility in medical affairs. She served as an Executive Medical Affairs Director and, in recent years, held the esteemed position of Global Patient Engagement Executive Director at Gilead Sciences.
Joining Gilead Sciences in 2000, Geraldine contributed significantly to various aspects of global medical affairs. Her responsibilities included the development of award-winning medical education programs both internally and externally, strategic partnerships with Key Opinion Leaders (KOLs), and overall strategy and operations. From 2019 to October 2021, she led the global patient engagement team, a newly established department focused on systematically incorporating the voice of the patient into the organization. Geraldine has actively engaged in research and has an extensive publication record.
Additionally, she served as an elected member of Patient Focused Medicine Development (PFMD) and maintains close collaboration with PFMD and various patient organizations.
Geraldine holds registrations as a General Nurse, District Nurse, and HIV Specialist Nurse, accumulating over 25 years of experience in the life science industry and healthcare.
With a strong background in financial leadership and M&A, Udi is passionate about helping companies achieve their full potential. Udi has experience spanning both organic scaling and strategic acquisitions, allowing to navigate the complexities of growth across diverse situations.
Most recently, Udi served as the Financial Director at Roboyo, an intelligent automation company. During his tenure, Udi played a pivotal role in scaling the organization from a handful of individuals to a global workforce of 500 employees. This remarkable growth was driven by a combination of organic initiatives and strategic acquisitions.
Prior to Roboyo, Udi spent several years in investment banking M&A, focusing specifically on the healthcare technology sector. In this role, Udi managed various investment processes, generating significant value for both the businesses he served and the shareholders of the target companies. These transactions were often critical inflection points, strategically positioning companies for the next stage of their growth journey.
Udi holds a Chartered Accountant designation and possess a strong academic foundation with a degree in Economics and Mathematics from the University of Pennsylvania and additional studies at Imperial College.
Chief Financial Officer
Jason Hart
Highly talented, proven leader with a rare combination of technical, business and commercial skills with the ability and knowledge to start new businesses, maximise resources, execute strategic plans, and build or transform teams to drive innovative and disruptive offerings at a global scale.
Jason has a proven track record in being a visionary in creating new technologies that create new markets and disrupt old and existing markets.
Jason has a reputation as being energetic, passionate and tenacious and a leader who has created a reputation as a world leader within the Cyber Security industry with a proven record of executing transformational change and experience in achieving a vision.
A commercially-minded and straightforward leader known for making complex business decisions and sophisticated technology simple and consistently delivering results by empowering and inspiring others to perform.
Proven track record in building solid relationships external to the business and across organisations at all levels to secure engagement and buy-in. Finally, Jason has the added benefit of having a very deep technical knowledge across all domains of cybersecurity and was instrumental in the introduction of the role CSO (Chief Security Officer) was a formal ethical hacker.
I have the proven ability to assist and transform organisations in achieving their goals:
– Product Strategic Vision – Venture Capital & Private Equity Experienced
– Cyber & Information Security – Key Note Conference Speaker
– Cloud Computing & Security – Thought Leader and Proven Visionary
– Internet of Things (IoT) Security – Strategic Business Planning
– Business Transformation – Secure Digital Transformation
– Change Agent & Management – Business-driven Technology Organisations
Andrew in 2004 them moved to a then small start-up biotech named Gilead Sciences and stayed for over 18 years. He started as a National Sales Manager, before moving into Marketing positions which culminated in the Marketing Director role for the HIV franchise for the UK & Ireland. He then moved into strategic planning roles within Gilead’s global organisation. This entailed working with over 80 countries worldwide in helping them plan for product launches and managing various product life cycles. The delivery was focused on market mapping, brand campaigns, selling strategies and pricing.
In 2017 Andrew took over the Business Unit Director role for Liver Disease and Emerging viruses for the UK & Ireland. The business was a $200m portfolio and involved a highly innovative agreement with NHS England to supply drugs and patient finding services to the health care system for 5 years. In 2020 Andrew lead the efforts commercially within the UK and Europe to successfully bring Remdesivir the first treatment for Covid to the market. Andrew also worked in anti-fungals, HDV and CAR-T cell therapy within Gilead.
Technology Advisor
Andrew has worked within the pharmaceutical industry for over 30 years in a variety of increasingly senior commercial positions. He started at Glaxo in Sales, before moving quickly into Market Access. He then held a number of managerial positions within primary and secondary care sales teams and Market Access. The disease areas covered in this period included Respiratory, Gastro, Dermatology, Antibiotics, Diabetes, Oncology, Mental Health and Neurology.
Andrew in 2004 them moved to a then small start-up biotech named Gilead Sciences and stayed for over 18 years. He started as a National Sales Manager, before moving into Marketing positions which culminated in the Marketing Director role for the HIV franchise for the UK & Ireland. He then moved into strategic planning roles within Gilead’s global organisation. This entailed working with over 80 countries worldwide in helping them plan for product launches and managing various product life cycles. The delivery was focused on market mapping, brand campaigns, selling strategies and pricing.
In 2017 Andrew took over the Business Unit Director role for Liver Disease and Emerging viruses for the UK & Ireland. The business was a $200m portfolio and involved a highly innovative agreement with NHS England to supply drugs and patient finding services to the health care system for 5 years. In 2020 Andrew lead the efforts commercially within the UK and Europe to successfully bring Remdesivir the first treatment for Covid to the market. Andrew also worked in anti-fungals, HDV and CAR-T cell therapy within Gilead.
